晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02228 晶泰控股

已收盘 07-20 16:08:22

7.210

+0.030

+0.42%

最高7.430	最低7.150	成交量3,814万
今开7.230	昨收7.180	日振幅3.90%
总市值310.25亿	流通市值310.25亿	总股本43.03亿
成交额2.77亿	换手率0.89%	流通股本43.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02228","market":"HK","secType":"STK","nameCN":"晶泰控股","latestPrice":7.21,"timestamp":1784534902001,"preClose":7.18,"halted":0,"volume":38135241,"delay":0,"changeRate":0.004178272980501428,"floatShares":4303000000,"shares":4303000000,"eps":0.03474485235309799,"marketStatus":"已收盘","change":0.03,"latestTime":"07-20 16:08:22","open":7.23,"high":7.43,"low":7.15,"amount":277450460,"amplitude":0.038997,"askPrice":7.21,"askSize":42000,"bidPrice":7.2,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":0.03474485235309799,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784597400000},"marketStatusCode":5,"adr":0,"listingDate":1718208000000,"exchange":"SEHK","adjPreClose":7.18,"openAndCloseTimeList":[[1784511000000,1784520000000],[1784523600000,1784534400000]],"volumeRatio":0.595893,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02228","defaultTab":"news","newsList":[{"id":"1129474730","title":"异动解读｜晶泰控股盘中下跌5.15%，报7.51港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129474730","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129474730?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:13","pubTimestamp":1784254398,"startTime":"0","endTime":"0","summary":"7月17日，晶泰控股盘中下跌5.15%，报7.51港元/股，成交额1.42亿港元。晶泰控股所在的生命科学工具和服务行业整体承压，个股中，药明生物跌4.48%，药明康德跌5.0%，英矽智能跌8.81%，药明合联跌7.34%，昭衍新药跌9.84%。晶泰控股有限公司是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司，业务涵盖药物发现解决方案及智能自动化解决方案两大板块。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131349015","title":"异动解读｜晶泰控股盘中上涨5.38%，报7.84港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131349015","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131349015?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:59","pubTimestamp":1784080759,"startTime":"0","endTime":"0","summary":"7月15日，晶泰控股盘中上涨5.38%，报7.84港元/股，成交额1.0亿港元。晶泰控股所在的生命科学工具和服务行业整体走强，个股中，药明生物涨5.34%，英矽智能涨8.27%，药明康德涨5.25%，昭衍新药涨14.5%，康龙化成涨5.0%。晶泰控股有限公司是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司，业务涵盖药物发现解决方案及智能自动化解决方案两大板块。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126040539","title":"异动解读｜晶泰控股盘中下跌5.7%，报7.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126040539","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126040539?lang=zh_cn&edition=full","pubTime":"2026-07-14 09:57","pubTimestamp":1783994223,"startTime":"0","endTime":"0","summary":"7月14日，晶泰控股盘中下跌5.7%，报7.15港元/股，成交额1.48亿港元。晶泰控股所在的生命科学工具和服务行业整体承压，个股中，药明生物跌2.79%，英矽智能跌4.27%，药明康德跌0.46%，金斯瑞生物科技跌4.33%，康龙化成跌2.34%。晶泰控股有限公司是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司，业务涵盖药物发现解决方案及智能自动化解决方案两大板块。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164473678","title":"晶泰控股更新6月股份变动月报，股本实现小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1164473678","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164473678?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:56","pubTimestamp":1783936562,"startTime":"0","endTime":"0","summary":"2026年7月13日，晶泰控股（02228）披露了截至2026年6月30日止的证券变动月报。报告显示，公司法定/注册股本为100,000,000,000股，每股面值USD 0.00001，法定/注册股本总额保持在USD 1,000,000，较上月底无变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650155944","title":"【券商聚焦】国海证券首予晶泰控股(02228)增持评级 指AI制药范式驱动增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2650155944","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650155944?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:30","pubTimestamp":1783582202,"startTime":"0","endTime":"0","summary":"研报核心观点聚焦公司“AI+机器人+Multi-Agent”研发范式。国海证券预计公司AI制药业务收入将逐渐提升，预测2026/2027/2028年营业收入分别为10.33/13.98/18.15亿元，归母净利润分别为0.04/0.89/2.35亿元。首次覆盖，给予“增持”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985487","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHAT","01477","AIPO","02228","KCE","VTHR","000750","AGIX","ARTY","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122510532","title":"晶泰控股更新2026年6月股份变动月报表，股本小幅增加97,918股","url":"https://stock-news.laohu8.com/highlight/detail?id=1122510532","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122510532?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:01","pubTimestamp":1783414915,"startTime":"0","endTime":"0","summary":"2026年7月7日，晶泰控股有限公司公布了截至2026年6月30日的股份变动月报表。公告显示，公司法定注册股本维持不变，仍为100,000,000,000股普通股，面值每股USD 0.00001，合计USD 1,000,000。报告期内无库藏股等其他股本减少情况，也未发生购回或注销股份活动。此外，2027年到期的零息可转债发行总额为HKD 2,866,000,000，如完全转换将对应206,931,407股，报告期内无新增转换。截至2026年6月末，公司合计已发行股份总数为4,303,469,679股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179518592","title":"异动解读｜晶泰控股盘中下跌5.13%，报7.77港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179518592","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179518592?lang=zh_cn&edition=full","pubTime":"2026-07-07 14:29","pubTimestamp":1783405794,"startTime":"0","endTime":"0","summary":"7月7日，晶泰控股盘中下跌5.13%，报7.77港元/股，成交额2.87亿港元。晶泰控股所在的生命科学工具和服务行业中，个股普遍承压，其中药明生物跌2.96%，药明康德跌3.79%，英矽智能跌4.62%，药明合联跌4.41%，康龙化成涨0.15%。晶泰控股是一家以AI与机器人技术驱动药物及材料科学研发的平台型企业，主要业务包括药物发现解决方案及智能自动化解决方案，在国内和国外市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158372102","title":"异动解读｜晶泰控股盘中上涨5.95%，CXO板块持续走强叠加多重利好延续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1158372102","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158372102?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:21","pubTimestamp":1783304467,"startTime":"0","endTime":"0","summary":"7月6日，晶泰控股盘中上涨5.95%，报8.37港元，成交额2.41亿港元。公司层面，7月2日晶泰控股授出约3498万份购股权及约868万个受限制股份单位，行使价7.48港元，彰显管理层激励信心；此前公司与国际知名药企达成超4亿美元AI药物发现战略合作，1亿美元股份回购计划自6月10日起持续实施，AI自主实验工作站落地中石化标志平台向材料科学领域拓展取得实质进展，多重利好持续催化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118898914","title":"异动解读｜晶泰控股盘中上涨5.35%，CXO板块持续回暖叠加多重利好催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1118898914","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118898914?lang=zh_cn&edition=full","pubTime":"2026-07-03 14:23","pubTimestamp":1783059802,"startTime":"0","endTime":"0","summary":"7月3日，晶泰控股盘中上涨5.35%，报7.88港元，成交额3.54亿港元。公司层面，7月2日晶泰控股授出合共约3498万份购股权及约868万个受限制股份单位，行使价7.48港元，彰显管理层激励信心；此前公司与国际知名药企达成超4亿美元AI药物发现战略合作，1亿美元股份回购计划自6月10日起持续实施，AI自主实验工作站落地中石化亦标志平台向材料科学领域拓展取得实质进展，多重利好持续催化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648507216","title":"晶泰控股(02228)授出合共3498.021万份购股权及合共约868.08万个受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2648507216","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648507216?lang=zh_cn&edition=full","pubTime":"2026-07-02 20:31","pubTimestamp":1782995473,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股(02228)公布，于2026年7月2日，公司根据2026年股份计划的条款向承授人授出合共3498.021万份购股权及合共约868.08万个受限制股份单位，惟各自须待接纳后方可作实。购股权的行使价为每股7.48港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02228","BK1617","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189170212","title":"异动解读｜晶泰控股盘中上涨5.1%，生命科学板块走强叠加近期多重利好持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1189170212","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189170212?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:15","pubTimestamp":1782958521,"startTime":"0","endTime":"0","summary":"7月2日，晶泰控股盘中上涨5.1%，报7.78港元，成交额2.91亿港元。消息面上，公司近期利好密集释放：AI自主实验工作站近日正式落地中石化，标志着其\"AI+机器人\"平台向材料科学领域拓展取得实质性进展；此前公司宣布与国际知名药企达成超4亿美元AI药物发现战略合作，聚焦GPCR靶点口服小分子疗法；同时1亿美元股份回购计划自6月10日起持续实施，彰显管理层对公司价值的信心。当日生命科学板块整体走强，金斯瑞生物科技涨4.17%，药明生物涨3.06%，药明合联涨2.89%，板块共振助推股价表现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648451313","title":"18C特专科技公司香港IPO总结：上半年13家上市 募资298.23亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648451313","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648451313?lang=zh_cn&edition=full","pubTime":"2026-07-01 15:38","pubTimestamp":1782891527,"startTime":"0","endTime":"0","summary":"三、目前递表及上市进展截至2026年6月30日，还在上市申请有效期的特专科技公司共14家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461835.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02228","BK1163","06082","BK1617","BK1141","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647340109","title":"晶泰控股午前涨逾15% 晶泰科技AI自主实验工作站近日落地中石化","url":"https://stock-news.laohu8.com/highlight/detail?id=2647340109","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647340109?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:51","pubTimestamp":1782705060,"startTime":"0","endTime":"0","summary":"　　晶泰控股早盘涨超14%，截至发稿，股价上涨14.82%，现报7.75港元，成交额7.30亿港元。　　长江证券发布研报称，随着人工智能与科学研究的深度融合，AI4S正从科研辅助工具升级为新一轮科研范式变革的重要基础设施。我们看好公司通过整合精准AI分子设计、自动化合成与高通量湿实验筛选三大核心能力，构建起“干实验设计+湿实验验证”的高效研发闭环，加速商业化兑现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-06-29/doc-iniezxay2289816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1617","CHAT","AIPO","BK1141","AGIX","02228","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647475483","title":"创新药概念全线扬升 晶泰控股(02228)涨逾14% 机构指创新药仍为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2647475483","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647475483?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:33","pubTimestamp":1782700428,"startTime":"0","endTime":"0","summary":"消息面上，华鑫证券新近研究表示，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。以恒瑞医药为代表的创新药企业，创新药的收入比重持续提升。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984679","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328277881.USD","LU0348735423.USD","LU2476274308.USD","01093","IE00BZ08YS42.EUR","LU1961090484.USD","02162","LU1969619763.USD","BK1574","LU0315179316.USD","LU1226287792.SGD","LU0348827113.USD","IE00B5MMRT66.SGD","LU1226287529.USD","LU0417516571.SGD","BK1583","LU1008478684.HKD","LU0417516902.SGD","LU0072913022.USD","09969","09995","LU2476274720.SGD","LU0634319403.HKD","LU1226288253.USD","LU1951186391.HKD","LU1720050803.USD","LU1960683339.HKD","159992","BK1141","02228","06978","IE00B543WZ88.USD","LU0348825331.USD","LU0348783233.USD","02157","LU0880133367.SGD","LU0348766576.USD","09926","IE00BZ08YR35.GBP","02637","LU0540923850.HKD","01530","HK0000165453.HKD","LU0140636845.USD","LU1993786604.SGD","LU0348784397.USD","LU0067412154.USD","LU0326950275.SGD","06855","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647342009","title":"港股异动 | 晶泰控股(02228.HK)早盘涨超14% 晶泰科技AI自主实验工作站近日落地中石化","url":"https://stock-news.laohu8.com/highlight/detail?id=2647342009","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647342009?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:24","pubTimestamp":1782699841,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02228","BK1141","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148240074","title":"异动解读｜晶泰控股盘中上涨6.07%，生命科学板块集体走强叠加多重利好催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1148240074","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148240074?lang=zh_cn&edition=full","pubTime":"2026-06-29 09:59","pubTimestamp":1782698343,"startTime":"0","endTime":"0","summary":"6月29日，晶泰控股盘中上涨6.07%，报7.22港元，成交额2.16亿港元。消息面上，公司近期利好密集释放：此前宣布与国际知名药企达成超4亿美元AI药物发现战略合作，聚焦GPCR靶点口服小分子疗法开发；同时启动1亿美元股份回购计划，自6月10日起实施。此外，国家系统性部署数据赋能AI发展，市场对公司物理AI基建价值重估预期升温。当日生命科学板块整体走强，康龙化成涨4.86%，药明生物涨4.18%，药明康德涨3.37%，板块共振进一步助推股价表现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644773208","title":"【券商聚焦】中信建投：生物制品板块跟随医药行业整体回调 考虑与资金因素有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2644773208","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644773208?lang=zh_cn&edition=full","pubTime":"2026-06-18 09:26","pubTimestamp":1781745972,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究认为：1）中药：板块本周跑赢大盘及医药指数。市场关注呼吸道疾病发病率、基药目录等进展；除此市场持续关注“四同药品”价格专项治理、中成药集采等外部政策环境变化等带来的影响。2）生物制品：板块本周跑输医药指数及大盘。本周板块跟随医药行业整体回调，考虑主要与资金因素有关。3）医药商业：板块本周跑输申万医药，跑赢大盘。药店板块主要关注5月同店数据；流通板块关注院内合规及红利标的。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","LU2399975544.HKD","LU2476274720.SGD","601066","BK1141","BK1585","LU0561508036.HKD","IE00BPRC5H50.USD","06821","02268","LU1719994722.HKD","09688","LU0588546209.SGD","01099","02228","IE00B3M56506.USD","LU0417516902.SGD","LU0348766576.USD","LU0348735423.USD","03933","BK1500","LU0540923850.HKD","BK1100","LU1720050803.USD","BK1515","BK1161","BK1574","BK1588","IE00B5MMRT66.SGD","BK1197","LU0417516571.SGD","LU2476274308.USD","LU0348767384.USD","SG9999004311.SGD","LU1770034418.SGD","02196","LU0348784397.USD","LU0348783233.USD","01789","LU0348827113.USD","LU1969619763.USD","02367","LU0640798160.USD","LU2328871848.SGD","01530","BK1207","LU1303224171.USD","SG9999014674.SGD","BK1191","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170717886","title":"异动解读｜晶泰控股盘中下跌5.18%，高估值回归压力叠加板块整体承压延续弱势","url":"https://stock-news.laohu8.com/highlight/detail?id=1170717886","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170717886?lang=zh_cn&edition=full","pubTime":"2026-06-16 14:42","pubTimestamp":1781592124,"startTime":"0","endTime":"0","summary":"6月16日，晶泰控股盘中下跌5.18%，报6.59港元/股，成交额2.55亿港元。消息面上，公司此前公布超4亿美元AI药物发现战略合作及1亿美元股份回购计划，但市场反应持续冷淡。尽管公司营收同比增长超200%并首次实现年度盈利，动态市盈率仍高达212倍，高估值回归压力持续主导股价走势。同时，港股通持股比例逼近50%买入上限，做空比例维持高位，资金结构矛盾加剧市场对利好催化的反应钝化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643253842","title":"晶泰科技(02228)AI自主实验工作站落地中石化，打造AI+材料表征智能化新标杆","url":"https://stock-news.laohu8.com/highlight/detail?id=2643253842","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643253842?lang=zh_cn&edition=full","pubTime":"2026-06-15 09:08","pubTimestamp":1781485722,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，全球领先的人工智能+机器人药物与新材料研发平台晶泰科技宣布，其与中石化(上海)石油化工研究院有限公司、北京精微高博仪器有限公司联合打造的“智能化物理/化学吸附分析自主实验工作站”正式投入运营，以智能化、自动化的材料表征驱动化工研发，为“AI for Science”的材料发现引擎打造了关键的物理载体与具身智能底座。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ARTY","BK1617","AIPO","AGIX","02228","CHAT","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107841572","title":"异动解读｜晶泰控股盘中下跌5.02%，利好落地后估值压力持续释放","url":"https://stock-news.laohu8.com/highlight/detail?id=1107841572","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107841572?lang=zh_cn&edition=full","pubTime":"2026-06-11 10:37","pubTimestamp":1781145472,"startTime":"0","endTime":"0","summary":"6月11日，晶泰控股盘中下跌5.02%，报6.62港元/股，成交额1.69亿港元。消息面上，公司近日接连发布超4亿美元AI药物发现战略合作及1亿美元股份回购计划，但市场反应冷淡。此前合作公告仅带动股价短暂高开4%即回落，回购计划亦未能扭转颓势。尽管公司营收同比增长超200%并首次实现年度盈利，但动态市盈率仍高达212倍，叠加生命科学板块整体承压，高估值回归压力持续主导股价走势。行业内药明合联跌5.47%，英矽智能跌6.58%，板块情绪偏弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://www.xtalpi.com","stockEarnings":[{"period":"1week","weight":-0.0934},{"period":"1month","weight":0.0928},{"period":"3month","weight":-0.2933},{"period":"6month","weight":-0.432},{"period":"1year","weight":0.1809},{"period":"ytd","weight":-0.241}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0103},{"period":"3month","weight":-0.0611},{"period":"6month","weight":-0.085},{"period":"1year","weight":0.0026},{"period":"ytd","weight":-0.0417}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"晶泰控股有限公司是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司。该公司主要经营两个业务。药物发现解决方案业务从事就新型药物发现工作为各类生物技术与制药公司和学术机构提供模块独立解决方案或与之合作。智能自动化解决方案业务从事提供固态研发服务及自动化化学合成服务。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.06643},{"month":2,"riseRate":0.285714,"avgChangeRate":0.016028},{"month":3,"riseRate":0,"avgChangeRate":-0.069153},{"month":4,"riseRate":0.666667,"avgChangeRate":0.048494},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.010585},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.023767},{"month":7,"riseRate":0.428571,"avgChangeRate":0.047576},{"month":8,"riseRate":0.5,"avgChangeRate":-0.032189},{"month":9,"riseRate":0.8,"avgChangeRate":0.065839},{"month":10,"riseRate":0.6,"avgChangeRate":0.092453},{"month":11,"riseRate":0.5,"avgChangeRate":0.05299},{"month":12,"riseRate":0.5,"avgChangeRate":-0.011625}],"exchange":"SEHK","name":"晶泰控股","nameEN":"XTALPI"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"晶泰控股,02228,晶泰控股股票,晶泰控股股票老虎,晶泰控股股票老虎国际,晶泰控股行情,晶泰控股股票行情,晶泰控股股价,晶泰控股股市,晶泰控股股票价格,晶泰控股股票交易,晶泰控股股票购买,晶泰控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}